



Asymptomatic UTI in Pregnant Women and Antibiotic Treatments

* **Huda Taher Ali**

Department of Biology, College of Science, Al-Muthanna University, Samawah, Iraq.

Corresponding author: Huda Taher Ali

Department of Biology, College of Science, Al-Muthanna University, Samawah, Iraq.

Received Date: 12 Dec. 2025

Published Date: 31 Jan. 2026

Abstract

Urinary tract infections UTI containing asymptomatic bacteriuria (ASB), exemplify an important clinical valiant through pregnancy, pretense menaces to together mothers and, fetus. Physiological variations rise predisposition. Culturing of urine leftovers diagnostic importants typical, communal clinic appearances involved perseverance, Lower abdominal, Pelvic pain, Dysuria, Fever, and Hematuria, culturing of urine was main diagnosing means used. *Escherichia coli* is them more dominant Gram-negative isolated bacteria, shadowed *Enterococcus faecalis*, *Pseudomonas aerogenosa*, *Staphylococcus epidermidis* is communal Gram-positive isolated bacteria, pH of urine wide-ranging, through Gram-positive infection interrelated with extra basic pH urine. Clinical manifestations of UTIs happening during pregnancy are dependable through latest researches. Gram negative bacterium, generally *Escherichia. coli* dominated. Culturing of urine remainders keystone of finding with pH range of urine possibly payment adjunctived analytic evidence.

Keywords: UTI, ASB, antibiotic sensitivity.

Introduction

Pregnant period the situation is most main menace aspect in UTIs. From 6 to 10% of pregnant have progress a Low Urinary Tract infection during pregnancy and the 10% of pregnancy hospitalizations are caused by UTI infections. Unrefined ASB bacteriuria is a danger cause for pyelonephritis and low weight at birth, preterm delivery. There are many physiological vagaries that happen during pregnancy and rises the risk of presenting UTI, ureteral dilatation secondary to the act of progesterone and uterine compression, vesicoureteral reflux, bladder stasis, enlarged glomerular filtration rate along glycosuria then aminoaciduria as well as raised, (pH). [1,2]

Peril Features

Many Diverse Menace Features for Emerging a Utis Through Pregnancy, Recurrent Uti of Asb, Renal Lithiasis, Urogynaecological Malformations, Vesicoureteral Reflux Failure of Kidney, Dm Type 2, Neurologicaai Disorder Incompleted Emptying, Neurogenic Bladder, Etc., Disease of Sickle Cell Chlamydia Trachomatis Infections, Multiparty and Low Socioeconomic Levels. [3]

Bacterial isolation

Gram negative bacilli; *E. coli*, from enter bacterial normal flora is chief public bacterium complicated in mainstream of these infections while *Pseudomonas aerogenosa*, Gram-positive cocci; *Enterococcus faecalis*, *Staphylococcus epidermidis* are also insulated.[5]



TYPES OF UTIS

A- ASB

Asymptomatic bacteriuria ASB remains definite as existence of extra reach to 100,000 Colony Forming Units CFU in mill of microbes in cultured urine of a patients that have no clinically symptom of UTI. Greatest ASB happen in the initial trimester of pregnancy (Asymptomatic UTIs). UTI may happen without seeming symptoms, mainly during pregnancy, asymptomatic bacteriuria, instead, might cause worries if not addressed [6]

Pervasiveness

Its occur in 3-10% of all cases, 25% of entreat ASB resolve grow an acute pyelonephritis equated to 2% if they were treating with specific antibiotic, about more than 30% of the treated ABs resolve decline regardless of exact antibiotics treatment, hereafter standing of accomplishment gestation showing. Though rate and judgment of showing for ASB through pregnancy is open to discussion, gestational viewing is suggested at about 16 weeks or at the initial prenatal visit only if it is after the 12th week and it should only be frequent three-monthly if the pregnant woman has other menace factors (e.g. maternal kidney disease, pregnant with a solitary kidney, history of a kidney transplant, renal lithiasis, history of recurrent pyelonephritis or vesicoureteral reflux. [7]

Best antibiotics that castoff to treatment are (an anti gram) is typically available as the microbiology diagnosis.

1- Fosfomycin trometamol, 3 gm orally (single dose isolated from meal) is the good treatments, never needed for order a second dosage after 48 to 72 hour.

2- in case bacteriuria was affected by *E. faecalis*, treatments of best select shall be, Amoxicillins 500 mg all 8 hrs. for 4 to 7 days.

3- patient with allergy or resistance to fosfomycin, must use an antibiotic affording to anti gram, charitable precedence to 1st, 2nd generations cephalosporin and ducking using of amoxicillin clavulanic acid as extreme as promising, if Cefixime is do admin, using dose of 400 mg in 24 hrs. for 3 day, others antibiotic must be controlled for 4 to 7 days.

4- situation of beta lactam allergic case or resistant of Fosfomycins, Nitrofurantoin 50- 100 mg for 6 hrs. orally may use for 4 to 7 days, another alternate if no others practical medicines, use Cotrimoxazole, Category C160-800 mg every 12 hrs. for 3-5 days. [8,9]

select a lower-Spectrum antibiotic: Cefuroxime, Fosfomycin trometamol Amoxicillin 500 mg; Cefuroxime 250 mg; Amoxicillin-clavulanic acid 500-125mg, Ampicillins, Cephalosporin, Cephalexin, Erythromycin, Nitrofurantoin; and Trimethoprim-sulfamethoxazole.

Recurrent Complicated UTIs:

The ideologies of considering recurrent complicated UTI contain initial using of broad-spectrum antibiotic. with alteration of antibiotic reporting based on culture outcomes, and challenges to sack any present urinary impediment based on the result of imaging trainings. Antibiotics regimen and treatment recommendations are not definite in this patient population, the varied variability of inclining factors and causative organism, and the variable antibiotic resistance assortments, make uniform recommendations challenging. Antibiotic medley must be based on community resistance arrays, and empiric initial treatment must be directed by likely organism. [10]

For pregnant treatment choice should be careful owing to the endangerment of antibiotics activity on fetus. [11]

Materials and Methods

a- Study design

50 Urine sample were accumulated from individually patient before taking any antibiotic as treatment by means of the midstream clean-catch technique in a sterilized urine containers or use a distinctive tubes for pediatric sample then all samples were cultured on UTI Chrome agar and Moller Hinton agar for antibiotic sensitivity, then each plate was incubate in aerobic condition at 37°C for 24 hrs. and recognized using typical protocols of microbiology. The isolate was tested for antibiotic susceptibility on Mueller- Hinton agar. [13,14]

b- Study population

Study population involved pregnant people aged 17–35 years who were 9 to 32 weeks' gestation, the samples were collected during September, 2025, and January 2026. [15]

Results

Four bacterial species were identified, 0.51% (26/50) Gram Negative, 0.47% (24/50) Gram-Positive). *E. coli* is the greatest commonly isolated bacteria 0.27% (14/50). *Enterococcus faecalis* 0.25% (13/50), *Pseudomonas aeruginosa* 0.24% (12/50) and *Staphylococcus epidermidis* 0.21% (11/50).

Table 1: Chi-square analysis of the Anti-biotic associated with UTI patients.

Anti biotic	p-value	Statistical Results
AMP	0.644	Non significant
AMX	0.215	Non significant
Ceph	0.0028	High significant
Fos	0.085	Non significant
Cefuro	0.111	Non significant
AMC	0.255	Non significant
Ery	0.085	Non significant
Nitro	0.111	Non significant
TMP	0.038	significant

*The *p*-value is < .00001. The result is significant at *p* < .05 for Ceph *p*=0.0028 and TMP *p*= 0.038 while the result of other antibiotic is no significant.

Conclusion

Escherichia. coli was the highest frequently isolated bacteria then *Enterococcus feacalis*, the outcome can denote that *Enterococcus feacalis*, is flattering progressively communal as an etiological cause of UTIs an elevated resistant headed for two antibiotics cephalosporin (*p*=0.0028) and TMP (*P*=0.038). The outcomes highpoint essential to observe for therapeutics guideline to treatment UTI and other diseases that caused by bacteria and not abuse antibiotic to avoid the appearance of multidrugs resistance bacterium.

References

1. Chukwudozie, O. S. (2014). *Prevalence and antimicrobial susceptibility pattern of urinary tract infection (UTI) among pregnant women in Afikpo, Ebonyi State, Nigeria. American Journal of Life Sciences, 2*(2), 46. <https://doi.org/10.11648/j.ajls.20140202.12>
2. Salvatore, S., Salvatore, E., Cattoni, G., Siesto, M., Serati, P., Sorice, M., & Torella, M. (2011). Urinary tract infections in women. *European Journal of Obstetrics & Gynecology and Reproductive Biology, 156*(2), 131–136. <https://doi.org/10.1016/j.ejogrb.2011.01.028>
3. Tenaillon, O., Skurnik, D., Picard, B., & Denamur, E. (2010). The population genetics of commensal *Escherichia coli*. *Nature Reviews Microbiology, 8*(3), 207–217. <https://doi.org/10.1038/nrmicro2298>
4. Renard, J., Ballarini, S., Mascarenhas, T., et al. (2014). Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: A prospective, observational study. *Infectious Diseases and Therapy, 4*, 125–135. <https://doi.org/10.1007/s40121-014-0051-6>
5. El-Shazly, D. A., Nasef, S. A., Mahmoud, F. F., & Jonas, D. (2017). Expanded spectrum β-lactamase-producing *Escherichia coli* isolated from chickens with colibacillosis in Egypt. *Poultry Science, 96*(7), 2375–2384. <https://doi.org/10.3382/ps/pew493>
6. Mangiarotti, P., Pizzini, C., & Fanos, V. (2000). Antibiotic prophylaxis in children with relapsing urinary tract infections: Review. *Journal of Chemotherapy, 12*(2), 115–123. <https://doi.org/10.1179/joc.2000.12.2.115>
7. Ourani, M., Honda, N. S., MacDonald, W., & Roberts, J. (2021). Evaluation of evidence-based urinalysis reflex to culture criteria: Impact on reducing antimicrobial usage. *International Journal of Infectious Diseases, 102*, 40–44. <https://doi.org/10.1016/j.ijid.2020.09.1471>
8. Cai, T., Mazzoli, S., Mondaini, N., et al. (2012). The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: To treat or not to treat? *Clinical Infectious Diseases, 55*(6), 771–777. <https://doi.org/10.1093/cid/cis534>
9. Dutta, R., Stothers, L., & Ackerman, A. L. (2024). Manipulating the gut microbiome in urinary tract infection-prone patients. *Urologic Clinics of North America, 51*(4), 525–536. <https://doi.org/10.1016/j.ucl.2024.07.016>
10. Spaulding, C. N., Klein, R. D., Schreiber, H. L. IV, Janetka, J. W., & Hultgren, S. J. (2018). Precision antimicrobial therapeutics: The path of least resistance? *NPJ Biofilms and Microbiomes, 4*, 4. <https://doi.org/10.1038/s41522-018-0048-3>
11. Kettlewell, R., Jones, C., Felton, T. W., Lagator, M., & Gifford, D. R. (2024). Insights into durability against resistance from the antibiotic nitrofurantoin. *NPJ Antimicrobial Resistance, 2*(1), 41. <https://doi.org/10.1038/s44259-024-00056-1>
12. Lifshitz, E., & Kramer, L. (2000). Outpatient urine culture: Does collection technique matter? *Archives of Internal*

Medicine, 160(16), 2537–2540. <https://doi.org/10.1001/archinte.160.16.2537>

13. Clinical and Laboratory Standards Institute. (2024). *Performance standards for antimicrobial susceptibility testing* (34th ed., CLSI supplement M100). Clinical and Laboratory Standards Institute.
14. Nickel, J. C., Kelly, K. L., Griffin, A., Elterman, D., Clark-Pereira, J., & Doiron, R. C. (2024). MV140 sublingual vaccine reduces recurrent urinary tract infection in women: Results from the first North American clinical experience study. *Canadian Urological Association Journal*, 18(2), 25–31.